Ashwin Prakash1,2, Leslie B Gordon3,4, Monica E Kleinman3,5, Ellen B Gurary6, Joseph Massaro6, Ralph D'Agostino6, Mark W Kieran7, Marie Gerhard-Herman8, Leslie Smoot1,2. 1. Department of Cardiology, Boston Children's Hospital, Harvard Medical School, Boston, Massachusetts. 2. Department of Pediatrics, Harvard Medical School, Boston, Massachusetts. 3. Department of Anesthesiology, Preoperative and Pain Medicine, Boston Children's Hospital, Harvard Medical School, Boston, Massachusetts. 4. Department of Pediatrics, Hasbro Children's Hospital, Warren Alpert Medical School of Brown University, Providence, Rhode Island. 5. Department of Critical Care Medicine, Boston Children's Hospital, Harvard Medical School, Boston, Massachusetts. 6. Department of Mathematics and Statistics, Boston University, Harvard Clinical Research Institute, Boston, Massachusetts. 7. Division of Hematology/Oncology, Boston Children's Hospital, Harvard Medical School, Boston, Massachusetts. 8. Department of Cardiovascular Medicine, Brigham and Women's Hospital, Boston, Massachusetts.
Abstract
Importance: Hutchinson-Gilford progeria syndrome (HGPS) is an ultrarare disorder associated with premature death due to cardiovascular events during the second decade of life. However, because of its rarity (107 identified living patients), the natural history of cardiac disease remains uncharacterized. Therefore, meaningful cardiac end points for clinical trials have been difficult to establish. Objective: To examine the course of appearance of cardiac abnormalities in patients with HGPS to identify meaningful cardiac end points for use in future clinical trials. Design, Setting, and Participants: In this prospective, cross-sectional, observational study, 27 consecutive patients with clinically and genetically confirmed classic HGPS were evaluated at a single center for 1 visit from July 1, 2014, through February 29, 2016, before initiation of treatment. Exposure: Classic HGPS. Main Outcomes and Measures: Echocardiography was used to assess ventricular and valve function using standard techniques. Diastolic left ventricular (LV) function was assessed using tissue Doppler imaging. Previously published normative data were used to adjust findings to age and body size. Results: This study included 27 patients (median age, 5.6 years; age range, 2-17 years; 15 [56%] male). Among echocardiographic indicators, LV diastolic dysfunction, defined as a tissue Doppler septal or lateral early velocity z score less than -2, was the most prevalent abnormality, seen in 16 patients (59%). Diastolic dysfunction was seen in all age groups, and its prevalence increased with age, mirroring findings seen during normal aging. Indicators of LV diastolic function were more abnormal in older patients. The z scores for lateral and septal early velocities were lower (r = -0.77, P < .001; and r = -0.66, P < .001, respectively), whereas those for the ratio of early mitral inflow velocity to early diastolic tissue Doppler myocardial velocity were higher (r = 0.80, P < .001; and r = 0.72, P < .001, respectively) in older patients. Other echocardiographic findings, including LV hypertrophy, LV systolic dysfunction, and valve disease, were less prevalent in the first decade and were seen more frequently in the second decade. Conclusions and Relevance: In this largest-to-date cohort of patients with HGPS, LV diastolic dysfunction was the most prevalent echocardiographic abnormality and its prevalence increased with aging. Echocardiographic indicators of LV diastolic function may be useful end points in future clinical trials in this patient population.
Importance: Hutchinson-Gilford progeria syndrome (HGPS) is an ultrarare disorder associated with premature death due to cardiovascular events during the second decade of life. However, because of its rarity (107 identified living patients), the natural history of cardiac disease remains uncharacterized. Therefore, meaningful cardiac end points for clinical trials have been difficult to establish. Objective: To examine the course of appearance of cardiac abnormalities in patients with HGPS to identify meaningful cardiac end points for use in future clinical trials. Design, Setting, and Participants: In this prospective, cross-sectional, observational study, 27 consecutive patients with clinically and genetically confirmed classic HGPS were evaluated at a single center for 1 visit from July 1, 2014, through February 29, 2016, before initiation of treatment. Exposure: Classic HGPS. Main Outcomes and Measures: Echocardiography was used to assess ventricular and valve function using standard techniques. Diastolic left ventricular (LV) function was assessed using tissue Doppler imaging. Previously published normative data were used to adjust findings to age and body size. Results: This study included 27 patients (median age, 5.6 years; age range, 2-17 years; 15 [56%] male). Among echocardiographic indicators, LV diastolic dysfunction, defined as a tissue Doppler septal or lateral early velocity z score less than -2, was the most prevalent abnormality, seen in 16 patients (59%). Diastolic dysfunction was seen in all age groups, and its prevalence increased with age, mirroring findings seen during normal aging. Indicators of LV diastolic function were more abnormal in older patients. The z scores for lateral and septal early velocities were lower (r = -0.77, P < .001; and r = -0.66, P < .001, respectively), whereas those for the ratio of early mitral inflow velocity to early diastolic tissue Doppler myocardial velocity were higher (r = 0.80, P < .001; and r = 0.72, P < .001, respectively) in older patients. Other echocardiographic findings, including LV hypertrophy, LV systolic dysfunction, and valve disease, were less prevalent in the first decade and were seen more frequently in the second decade. Conclusions and Relevance: In this largest-to-date cohort of patients with HGPS, LV diastolic dysfunction was the most prevalent echocardiographic abnormality and its prevalence increased with aging. Echocardiographic indicators of LV diastolic function may be useful end points in future clinical trials in this patient population.
Authors: Annachiara De Sandre-Giovannoli; Rafaëlle Bernard; Pierre Cau; Claire Navarro; Jeanne Amiel; Irène Boccaccio; Stanislas Lyonnet; Colin L Stewart; Arnold Munnich; Martine Le Merrer; Nicolas Lévy Journal: Science Date: 2003-04-17 Impact factor: 47.728
Authors: Sebastian Strigl; Rose Hardy; Julie S Glickstein; Daphne T Hsu; Linda J Addonizio; Jacqueline M Lamour; Ashwin Prakash Journal: Pediatr Cardiol Date: 2008-01-05 Impact factor: 1.655
Authors: José Rivera-Torres; Conrado J Calvo; Anna Llach; Gabriela Guzmán-Martínez; Ricardo Caballero; Cristina González-Gómez; Luis J Jiménez-Borreguero; Juan A Guadix; Fernando G Osorio; Carlos López-Otín; Adela Herraiz-Martínez; Nuria Cabello; Alex Vallmitjana; Raul Benítez; Leslie B Gordon; José Jalife; José M Pérez-Pomares; Juan Tamargo; Eva Delpón; Leif Hove-Madsen; David Filgueiras-Rama; Vicente Andrés Journal: Proc Natl Acad Sci U S A Date: 2016-10-31 Impact factor: 11.205
Authors: Maria Eriksson; W Ted Brown; Leslie B Gordon; Michael W Glynn; Joel Singer; Laura Scott; Michael R Erdos; Christiane M Robbins; Tracy Y Moses; Peter Berglund; Amalia Dutra; Evgenia Pak; Sandra Durkin; Antonei B Csoka; Michael Boehnke; Thomas W Glover; Francis S Collins Journal: Nature Date: 2003-04-25 Impact factor: 49.962
Authors: Robert D Goldman; Dale K Shumaker; Michael R Erdos; Maria Eriksson; Anne E Goldman; Leslie B Gordon; Yosef Gruenbaum; Satya Khuon; Melissa Mendez; Renée Varga; Francis S Collins Journal: Proc Natl Acad Sci U S A Date: 2004-06-07 Impact factor: 11.205
Authors: Melissa A Merideth; Leslie B Gordon; Sarah Clauss; Vandana Sachdev; Ann C M Smith; Monique B Perry; Carmen C Brewer; Christopher Zalewski; H Jeffrey Kim; Beth Solomon; Brian P Brooks; Lynn H Gerber; Maria L Turner; Demetrio L Domingo; Thomas C Hart; Jennifer Graf; James C Reynolds; Andrea Gropman; Jack A Yanovski; Marie Gerhard-Herman; Francis S Collins; Elizabeth G Nabel; Richard O Cannon; William A Gahl; Wendy J Introne Journal: N Engl J Med Date: 2008-02-07 Impact factor: 91.245
Authors: C M Gordon; R H Cleveland; K Baltrusaitis; J Massaro; R B D'Agostino; M G Liang; B Snyder; M Walters; X Li; D T Braddock; M E Kleinman; M W Kieran; L B Gordon Journal: Bone Date: 2019-05-08 Impact factor: 4.398
Authors: S-I Murtada; Y Kawamura; A W Caulk; H Ahmadzadeh; N Mikush; K Zimmerman; D Kavanagh; D Weiss; M Latorre; Z W Zhuang; G S Shadel; D T Braddock; J D Humphrey Journal: J R Soc Interface Date: 2020-05-27 Impact factor: 4.118
Authors: Selma Osmanagic-Myers; Attila Kiss; Christina Manakanatas; Ouafa Hamza; Franziska Sedlmayer; Petra L Szabo; Irmgard Fischer; Petra Fichtinger; Bruno K Podesser; Maria Eriksson; Roland Foisner Journal: J Clin Invest Date: 2018-12-18 Impact factor: 14.808
Authors: Magda R Hamczyk; Ricardo Villa-Bellosta; Víctor Quesada; Pilar Gonzalo; Sandra Vidak; Rosa M Nevado; María J Andrés-Manzano; Tom Misteli; Carlos López-Otín; Vicente Andrés Journal: EMBO Mol Med Date: 2019-04 Impact factor: 12.137